Aminocaproic acid tablets

This product is an antifibrinolytic drug. Plasminogen specifically binds to fibrin through the lysine binding site in its molecular structure, and then becomes plasmin under the action of activators. This enzyme can cleave the arginine and lysine peptide bonds in fibrin to form fibrin degradation products, dissolving blood clots. The chemical structure of this product is similar to lysine, and it binds to the lysine binding sites on plasminogen and plasmin, thereby inhibiting the binding of plasminogen to fibrin and preventing its activation, thereby inhibiting fibrinolysis. High concentrations (100 mg/L) directly inhibit the activity of plasmin and achieve a hemostatic effect.

Chemical name: 6-aminohexanoic acid

This product is white tablets.

It is suitable for the prevention and treatment of various bleeding caused by hyperfibrinolysis. (1) Bleeding caused by trauma or surgery of organs rich in plasminogen activators such as the prostate, urethra, lungs, liver, pancreas, brain, uterus, adrenal glands, and thyroid glands, and bleeding caused by excessive amounts of tissue plasminogen activator (t-PA), streptokinase, or urokinase. (2) It can be used as an adjuvant treatment for bleeding after tooth extraction or oral surgery or menorrhagia in hemophiliacs. (3) It can be used for symptomatic treatment of various bleeding such as upper gastrointestinal bleeding, hemoptysis, idiopathic thrombocytopenic purpura, and leukemia. It has a significant effect on general chronic oozing; it has a poor effect on bleeding caused by abnormal coagulation function; and it has no hemostatic effect on severe bleeding, massive bleeding from wounds, and bleeding from cancer.

Oral administration, 2g each time, 3-4 times a day, for 7-10 days or longer depending on the condition. The oral dose for children is 0.1g/kg/time, 3-4 times a day. This product is absorbed quickly and completely, and the effective concentration in the blood can be reached 1-2 hours after taking it.

⑴ This drug has certain side effects. As the dosage increases, the number of adverse reactions increases, the symptoms worsen and the duration of efficacy is shorter. It is now gradually used less. ⑵ Common adverse reactions are nausea, vomiting and diarrhea, followed by dizziness, itching, tinnitus, tinnitus, general discomfort, nasal congestion, rash, erythema, and no ejaculation. This is especially likely to occur when the daily dose exceeds 16g. ⑶ Postural hypotension, conjunctival and nasal mucosal congestion, etc. may occur due to vasodilation. ⑷ This product is excreted quickly in the urine and has a high urine concentration. It can inhibit the fibrinolytic effect of urokinase, form blood clots, and block the urinary tract. Therefore, patients with hematuria after urology surgery should use it with caution. ⑸ Thrombosis and heart disease are prone to occur

⑴; Use with caution in patients with bleeding after urethral surgery; ⑵; Avoid use in patients with thrombotic tendency or past vascular embolism; ⑶; Use with caution in patients with renal insufficiency.

⑴ This product has poor immediate hemostatic effect and should be used in combination with other hemostatic drugs for acute massive bleeding. ⑵ This product should not be mixed with hemostatic drugs for injection.

Keep tightly closed in a dry place.

0.5g

Lepu Pharmaceutical (Beijing) Co., Ltd.

• Founded in:

  1998-11-08

• Address:

  Room 2032, Block B, No. 9 Chaoqian Road, Science and Technology Park, Changping District, Beijing

• Tax NO.:

  91110114634394670K

• Registered Funds:

  38.26666667 million yuan

• Website:

  Log in to view

• Email:

  Log in to view